{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T10:48:35Z","timestamp":1774954115636,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Chongqing Science and Technology Bureau and Health Commission Joint Medical Project","award":["2025MSXM056"],"award-info":[{"award-number":["2025MSXM056"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-45831-4","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T11:07:11Z","timestamp":1774868831000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dvalue of serum biomarkers for identifying computed tomography abnormalities in male miners"],"prefix":"10.1038","volume":"16","author":[{"given":"Qiang","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liuqing","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Diao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"45831_CR1","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.jncc.2025.01.003","volume":"5","author":"Y Ji","year":"2025","unstructured":"Ji, Y. et al. The epidemiological landscape of lung cancer: Current status, temporal trend and future projections based on the latest estimates from GLOBOCAN 2022. J. Natl. Cancer Cent. 5, 278\u2013286. https:\/\/doi.org\/10.1016\/j.jncc.2025.01.003 (2025).","journal-title":"J. Natl. Cancer Cent."},{"key":"45831_CR2","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41571-023-00798-3","volume":"20","author":"A Leiter","year":"2023","unstructured":"Leiter, A., Veluswamy, R. R. & Wisnivesky, J. P. The global burden of lung cancer: Current status and future trends. Nat. Rev. Clin. Oncol. 20, 624\u2013639. https:\/\/doi.org\/10.1038\/s41571-023-00798-3 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"45831_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108232","volume":"240","author":"DN Weissman","year":"2022","unstructured":"Weissman, D. N. Progressive massive fibrosis: An overview of the recent literature. Pharmacol. Ther. 240, 108232. https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108232 (2022).","journal-title":"Pharmacol. Ther."},{"key":"45831_CR4","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.clon.2016.08.001","volume":"28","author":"DR Baldwin","year":"2016","unstructured":"Baldwin, D. R. & Callister, M. E. What is the optimum screening strategy for the early detection of lung cancer. Clin. Oncol. 28, 672\u2013681. https:\/\/doi.org\/10.1016\/j.clon.2016.08.001 (2016).","journal-title":"Clin. Oncol."},{"key":"45831_CR5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/rti.0000000000000538","volume":"36","author":"CI Henschke","year":"2021","unstructured":"Henschke, C. I. et al. The regimen of computed tomography screening for lung cancer: Lessons learned over 25 years from the international early lung cancer action program. J. Thorac. Imaging. 36, 6\u201323. https:\/\/doi.org\/10.1097\/rti.0000000000000538 (2021).","journal-title":"J. Thorac. Imaging."},{"key":"45831_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.lungcan.2013.01.002","volume":"80","author":"K Okamura","year":"2013","unstructured":"Okamura, K. et al. Diagnostic value of CEA and CYFRA 21\u2009\u2013\u20091 tumor markers in primary lung cancer. Lung Cancer. 80, 45\u201349. https:\/\/doi.org\/10.1016\/j.lungcan.2013.01.002 (2013).","journal-title":"Lung Cancer"},{"key":"45831_CR7","first-page":"477","volume":"19","author":"F Tas","year":"2000","unstructured":"Tas, F. et al. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer. J. experimental Clin. cancer research: CR. 19, 477\u2013481 (2000).","journal-title":"J. experimental Clin. cancer research: CR"},{"key":"45831_CR8","doi-asserted-by":"publisher","DOI":"10.3233\/tub-230016","volume":"46","author":"T Muley","year":"2024","unstructured":"Muley, T. et al. Prognostic value of tumor markers ProGRP, NSE and CYFRA 21\u2009\u2212\u20091 in patients with small cell lung cancer and chemotherapy-induced remission. Tumour Biol. 46, S219-s232. https:\/\/doi.org\/10.3233\/tub-230016 (2024).","journal-title":"Tumour Biol."},{"key":"45831_CR9","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1093\/labmed\/lmad020","volume":"54","author":"A Sun","year":"2023","unstructured":"Sun, A. Clinical role of serum tumor markers SCC, NSE, CA 125, CA 19\u2009\u2013\u20099, and CYFRA 21\u2009\u2013\u20091 in patients with lung cancer. Lab. Med. 54, 638\u2013645. https:\/\/doi.org\/10.1093\/labmed\/lmad020 (2023).","journal-title":"Lab. Med."},{"key":"45831_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.112876","volume":"28","author":"C P\u00e9rez-D\u00edaz","year":"2025","unstructured":"P\u00e9rez-D\u00edaz, C. et al. Associations of internal persistent organic pollutant levels with sex hormones: An analysis by sex and menopausal status in a Spanish cohort. iScience 28, 112876. https:\/\/doi.org\/10.1016\/j.isci.2025.112876 (2025).","journal-title":"iScience"},{"key":"45831_CR11","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1002\/cam4.493","volume":"4","author":"ZH Zhang","year":"2015","unstructured":"Zhang, Z. H., Han, Y. W., Liang, H. & Wang, L. M. Prognostic value of serum CYFRA21-1 and CEA for non-small-cell lung cancer. Cancer Med. 4, 1633\u20131638. https:\/\/doi.org\/10.1002\/cam4.493 (2015).","journal-title":"Cancer Med."},{"key":"45831_CR12","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.21037\/tlcr-2024-1180","volume":"14","author":"R Sawada","year":"2025","unstructured":"Sawada, R. et al. Utility of serum CYFRA 21\u2009\u2212\u20091 as a prognostic biomarker in ALK-positive non-small cell lung cancer treated with ALK-TKIs: A retrospective cohort study. Transl. Lung Cancer Res. 14, 1986\u20132000. https:\/\/doi.org\/10.21037\/tlcr-2024-1180 (2025).","journal-title":"Transl. Lung Cancer Res."},{"key":"45831_CR13","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.21037\/tlcr-24-190","volume":"13","author":"N Kataoka","year":"2024","unstructured":"Kataoka, N. et al. CYFRA 21\u2009\u2212\u20091 predicts efficacy of combined chemoimmunotherapy in patients with advanced non-small cell lung cancer: A prospective observational study. Transl. Lung Cancer Res. 13, 1929\u20131937. https:\/\/doi.org\/10.21037\/tlcr-24-190 (2024).","journal-title":"Transl. Lung Cancer Res."},{"issue":"7","key":"45831_CR14","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1002\/(SICI)1097-0142(19960401)77:7<1274::AID-CNCR7>3.0.CO;2-I","volume":"77","author":"M Muraki","year":"1996","unstructured":"Muraki, M. et al. Assessment of serum CYFRA 21\u2009\u2212\u20091 in lung cancer. Cancer 77(7), 1274\u20131277 (1996).","journal-title":"Cancer"},{"key":"45831_CR15","doi-asserted-by":"publisher","first-page":"995","DOI":"10.4161\/cbt.11.12.15526","volume":"11","author":"XY Chu","year":"2011","unstructured":"Chu, X. Y., Hou, X. B., Song, W. A., Xue, Z. Q. & Zhang, L. B. Diagnostic values of SCC, CEA, Cyfra21-1 and NSE for lung cancer in patients with suspicious pulmonary masses: A single center analysis. Cancer Biol. Ther. 11, 995\u20131000 (2011).","journal-title":"Cancer Biol. Ther."},{"key":"45831_CR16","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1164\/rccm.201404-0603OC","volume":"193","author":"R Molina","year":"2016","unstructured":"Molina, R. et al. Assessment of a combined panel of six serum tumor markers for lung cancer. Am. J. Respir. Crit. Care Med. 193, 427\u2013437. https:\/\/doi.org\/10.1164\/rccm.201404-0603OC (2016).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"45831_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102769","volume":"75","author":"Y Jin","year":"2024","unstructured":"Jin, Y. et al. Development and validation of an integrated system for lung cancer screening and post-screening pulmonary nodules management: a proof-of-concept study (ASCEND-LUNG). EClinicalMedicine 75, 102769. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102769 (2024).","journal-title":"EClinicalMedicine"},{"key":"45831_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/s2589-7500(23)00125-5","volume":"5","author":"J He","year":"2023","unstructured":"He, J. et al. Accurate classification of pulmonary nodules by a combined model of clinical, imaging, and cell-free DNA methylation biomarkers: A model development and external validation study. Lancet. Digit. Health 5, e647-e656. https:\/\/doi.org\/10.1016\/s2589-7500(23)00125-5 (2023).","journal-title":"Lancet. Digit. Health"},{"key":"45831_CR19","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/s1053-2498(01)00373-4","volume":"20","author":"D Hadjiliadis","year":"2001","unstructured":"Hadjiliadis, D., Tapson, V. F., Davis, R. D. & Palmer, S. M. Prognostic value of serum carcinoembryonic antigen levels in patients who undergo lung transplantation. J. Heart Lung Transplant. 20, 1305\u20131309. https:\/\/doi.org\/10.1016\/s1053-2498(01)00373-4 (2001).","journal-title":"J. Heart Lung Transplant."},{"key":"45831_CR20","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.21037\/tlcr-21-833","volume":"10","author":"H Chen","year":"2021","unstructured":"Chen, H. et al. Prognostic significance of postoperative longitudinal change of serum carcinoembryonic antigen level in patients with stage I lung adenocarcinoma completely resected by single-port video-assisted thoracic surgery: A retrospective study. Transl. Lung Cancer Res. 10, 3983\u20133994. https:\/\/doi.org\/10.21037\/tlcr-21-833 (2021).","journal-title":"Transl. Lung Cancer Res."},{"key":"45831_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-019-1828-0","volume":"17","author":"MG Dal Bello","year":"2019","unstructured":"Dal Bello, M. G. et al. The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients. J. Transl. Med. 17, 74. https:\/\/doi.org\/10.1186\/s12967-019-1828-0 (2019).","journal-title":"J. Transl. Med."},{"key":"45831_CR22","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920952994","volume":"12","author":"FG Dall\u2019Olio","year":"2020","unstructured":"Dall\u2019Olio, F. G. et al. CEA and CYFRA 21\u2009\u2212\u20091 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors. Ther. Adv. Med. Oncol. 12, 1758835920952994. https:\/\/doi.org\/10.1177\/1758835920952994 (2020).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"45831_CR23","doi-asserted-by":"publisher","first-page":"S163","DOI":"10.3233\/tub-220042","volume":"46","author":"T Muley","year":"2024","unstructured":"Muley, T. et al. CYFRA 21\u2009\u2212\u20091, CA 125 and CEA provide additional prognostic value in NSCLC patients with stable disease at first CT scan. Tumour Biol. 46, S163-s175. https:\/\/doi.org\/10.3233\/tub-220042 (2024).","journal-title":"Tumour Biol."},{"key":"45831_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-020-01894-9","volume":"18","author":"Z Tian","year":"2020","unstructured":"Tian, Z. et al. Prognostic value of neuron-specific enolase for small cell lung cancer: A systematic review and meta-analysis. World J. Surg. Oncol. 18, 116. https:\/\/doi.org\/10.1186\/s12957-020-01894-9 (2020).","journal-title":"World J. Surg. Oncol."},{"key":"45831_CR25","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1164\/ajrccm.150.1.8025740","volume":"150","author":"J Collazos","year":"1994","unstructured":"Collazos, J., Esteban, C., Fern\u00e1ndez, A. & Genoll\u00e1, J. Measurement of the serum tumor marker neuron-specific enolase in patients with benign pulmonary diseases. Am. J. Respir. Crit. Care Med. 150, 143\u2013145. https:\/\/doi.org\/10.1164\/ajrccm.150.1.8025740 (1994).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"45831_CR26","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1177\/172460089801300305","volume":"13","author":"M Szturmowicz","year":"1998","unstructured":"Szturmowicz, M., Burakowski, J., Tomkowski, W., Sakowicz, A. & Filipecki, S. Neuron-specific enolase in non-neoplastic lung diseases, a marker of hypoxemia? Int. J. Biol. Mark. 13, 150\u2013153. https:\/\/doi.org\/10.1177\/172460089801300305 (1998).","journal-title":"Int. J. Biol. Mark."},{"key":"45831_CR27","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1055\/s-0043-1766119","volume":"44","author":"DH Yates","year":"2023","unstructured":"Yates, D. H. Physiology and biomarkers for surveillance of occupational lung disease. Semin. Respir. Crit. Care Med. 44, 349\u2013361. https:\/\/doi.org\/10.1055\/s-0043-1766119 (2023).","journal-title":"Semin. Respir. Crit. Care Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-45831-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-45831-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-45831-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T09:50:32Z","timestamp":1774950632000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-45831-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["45831"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-45831-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]},"assertion":[{"value":"5 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10609"}}